2024年11月20日

 

致：

BiolineRx Ltd.

2 號哈瑪亞恩街

Modi’in 7177871，以色列

 

回覆： BiolineRx有限公司

 

女士們，先生們：

 

我們已充當以色列BiolineRx有限公司的律師，該公司根據以色列法律成立（“BiolineRx”）有關公司在註冊直接發行中發行和銷售的（i）公司的4,121,493份美國存托股份（“公司”），以色列交易所向董事會的股份提供其他棱鏡。ADSs交付方提供的ADSs每一張ADS代表公司每股面值0.10新以色列錫克爾的15股普通股（“普通股 ），（ii）預資助型認股權證，可購買高達12,349,956張ADSs（“預購權證”）; 和（iii）可購買高達8,235,724張ADSs（“普通認股權證” 與預先資助的購股權證合併後，「認股權證」， 根據2024年11月20日簽署的證券購買協議（「購買協議」），由公司及相應投資者之間訂立。行使購股權證後可發行的ADS將在此後稱為「期權ADSs.”

 

為配合此事項，我們已審閱原件或經我們認證或以其他形式滿足我們的要求的影印本或副本：<br>(i) 表單F-3，文件編號333-276323的登記聲明（「申報書註冊聲明和招股說明書（“說明書”）」提交給美國證券交易委員會（「”）根據1933年修訂版的證券法（“證券法根據截至目前修訂的文件，以及公司於2024年11月21日根據證券法第424(b)(5)條提交的概況補充，即「」說明書最新證券資料；(ii) 公司的組織章程副本，根據現行修訂並生效中的是「」章程”); (iii) resolutions of the board of directors of the Company (the “董事會”) and committees of the Board which have heretofore been approved and that relate to the Registration Statement, the Prospectus Supplement and the actions to be taken under the Purchase Agreement; and (iv) such other corporate records, agreements, documents and other instruments, and such certificates or comparable documents of public officials and of officers and representatives of the Company as we have deemed relevant and necessary as a basis for the opinions hereafter set forth.  We have also made inquiries of such officers and representatives as we have deemed relevant and necessary as a basis for the opinions hereafter set forth.

 

In such examination, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as reproduced or certified copies and the authenticity of the originals of such latter documents.  We have assumed the same to have been properly given and to be accurate.  We have also assumed the truth of all facts communicated to us by the Company and that all consents and minutes of meetings of committees of the Board, the Board and the shareholders of the Company that have been provided to us are true and accurate and have been properly prepared in accordance with the Articles and all applicable laws.

 

Based upon and subject to the foregoing, we are of the opinion that the Ordinary Shares represented by the Offered ADSs and the Warrant ADSs have been duly authorized for issuance and sale pursuant to the Purchase Agreement and, in the case of the Warrant ADSs, the Warrants, by all necessary corporate action on the part of the Company and, when issued, delivered and paid for in accordance with the terms and conditions of the Purchase Agreement, and, with respect to the Warrant ADSs, the Warrants, will be validly issued, fully paid and non-assessable.

 

我們事務所的成員被承認為以色列國家律師協會的成員，我們對其他司法管轄區的法律不表達任何意見。這份意見僅限於此處所述事項，沒有暗示或暗示超出明確陳述事項以外的意見。

 

我們特此同意將此意見作為附表附加到公司向委員會提交的6-k表格報告中，以便關閉購買協議下的交易​​和在《說明書補充》中提及本事務所的“法律事項”和“民事責任的可強制執行性”標題下。在給出此同意時，我們並不因此承認我們是《證券法》所指的“專家”。

 

本意見書來信日期作出並且我們不擔保有義務通知您在此日期之後我們注意到可能改變、影響或修改本意見所表達之事實、情況、事件或發展。

 

您真誠的，   /s/ 菲舍爾（FBC & Co.）